Harrow Health (HROW) Alleged Concealing of US DOJ Investigation and US FDA Warning Letter Case

• In February, report was published alleging Harmony’s several problems with US authorities.

• On it, $HROW fell 3.2%, losing $18M+ of shareholder value.

• Investors may have grounds to suspect Harmony of concealing material information.

On February 22, 2023, Bonitas Research published a report alleging, among other things,

• that Harrow had concealed a U.S. DOJ investigation into its sales practices;

• that it had engaged in suspect transactions with former subsidiaries;

• that Harrow failed to disclose a warning letter from the U.S. FDA for making false and misleading marketing claims, but later issued a nationwide recall.

On this news, $HROW fell 3.2% and lost over $18 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that Harrow Health and its executives failed to timely disclose operational and regulatory setbacks, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.